Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Ruby Khatun Khatun
    Ruby Khatun Khatun
      • Home
      • Ruby Khatun Khatun

      Articles By : Ruby Khatun Khatun

      FDA approves new antibacterial drug Vabomere to treat complicated urinary tract infections

      FDA approves new antibacterial drug Vabomere to treat complicated urinary tract infections

      Ruby Khatun Khatun2 Sept 2017 10:00 AM IST
      The U.S. Food and Drug Administration (FDA) approved Vabomere for adults with complicated urinary tract infections (cUTI), including a type of kidney...
      Zydus Cadila gets USFDA nod for anti-dementia drug

      Zydus Cadila gets USFDA nod for anti-dementia drug

      Ruby Khatun Khatun2 Sept 2017 9:49 AM IST
      New Delhi: Drug firm Zydus Cadila on Friday said it has received the final nod from the US health regulator to market Donepezil Hydrochloride tablets...
      AstraZeneca aims to offset drug setback at big cancer congress

      AstraZeneca aims to offset drug setback at big cancer congress

      Ruby Khatun Khatun2 Sept 2017 9:30 AM IST
      LONDON: After last month’s big clinical trial setback in lung cancer, AstraZeneca will seek to rebuild its oncology reputation next week when it...
      SC restrains Singh brothers from diluting any stake in Fortis Healthcare

      SC restrains Singh brothers from diluting any stake in Fortis Healthcare

      Ruby Khatun Khatun1 Sept 2017 3:54 PM IST
      New Delhi: The Supreme Court on Thursday restrained brothers Malvinder Singh and Shivinder Singh from diluting any stake in the Fortis Healthcare.The...
      Arrow Pharma acquires Australian operations of Amneal Pharma

      Arrow Pharma acquires Australian operations of Amneal Pharma

      Ruby Khatun Khatun1 Sept 2017 1:38 PM IST
      New Delhi: Drug firm Strides Shasun said its arm Arrow Pharmaceuticals has acquired Australian operations of Amneal Pharmaceuticals for a total...
      Dr Reddys settles patent row with Vivus on weight management drug

      Dr Reddys settles patent row with Vivus on weight management drug

      Ruby Khatun Khatun1 Sept 2017 1:29 PM IST
      Hyderabad: Nasdaq-listed Vivus Inc on Thursday entered into a settlement agreement with Dr Reddy's Laboratories to resolve a long-pending patent...
      Panacea Biotech promoters may demerge real estate business into separate firm

      Panacea Biotech promoters may demerge real estate business into separate firm

      Ruby Khatun Khatun1 Sept 2017 1:29 PM IST
      New Delhi: Drug firm Panacea Biotec on Wednesday said its promoters have entered into a family agreement under which they plan to demerge the...
      AstraZeneca taps AI for drug discovery in deal with Berg

      AstraZeneca taps AI for drug discovery in deal with Berg

      Ruby Khatun Khatun1 Sept 2017 9:45 AM IST
      LONDON: AstraZeneca has forged a research collaboration with Boston-based Berg, a specialist in artificial intelligence for drug hunting, in the...
      Advertising budget for Obamacare to be cut 90 percent -US health agency

      Advertising budget for Obamacare to be cut 90 percent -US health agency

      Ruby Khatun Khatun1 Sept 2017 9:27 AM IST
      WASHINGTON: The U.S. Centers for Medicare and Medicaid Services said on Thursday it plans to spend $10 million on advertising for the upcoming...
      Zydus Cadila receives final approval from USFDA for Aspirin and extended release Dipyridamole capsules

      Zydus Cadila receives final approval from USFDA for Aspirin and extended release Dipyridamole capsules

      Ruby Khatun Khatun31 Aug 2017 11:00 AM IST
      Mumbai: Pharma major, Zydus Cadila said that company received final approval from the US Food and Drug Administration (USFDA) to market Aspirin and...
      US clears first LIVING DRUG, developed by Novartis for leukemia treatment, cost- 475,000 dollar

      US clears first LIVING DRUG, developed by Novartis for leukemia treatment, cost- 475,000 dollar

      Ruby Khatun Khatun31 Aug 2017 11:00 AM IST
      Opening a new era in cancer care, the Food and Drug Administration on Wednesday approved the first treatment that genetically engineers patients’ own...
      AstraZeneca strikes 400 million dollar Parkinsons drug deal with Takeda

      AstraZeneca strikes 400 million dollar Parkinsons drug deal with Takeda

      Ruby Khatun Khatun31 Aug 2017 10:30 AM IST
      LONDON: AstraZeneca is to receive up to $400 million from Takeda Pharmaceutical after striking a deal for the Japanese company to co-develop an...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok